<DOC>
	<DOCNO>NCT00863005</DOCNO>
	<brief_summary>The purpose study assessment barrier impairment , clinical skin condition bacterial colonization status patient atopic eczema follow topical treatment K201 cream comparator twice daily 4-week treatment period .</brief_summary>
	<brief_title>Assessment Effects Barrier Impairment , Clinical Features Bacterial Colonization Topical Formulations Patients With Atopic Eczema ; Phase IIa , Single-center , Randomized , Observer-blind Study</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>sign write informed consent obtain ; male female patient , 18 year old ; manifest atopic eczema diagnose accord Hanifin Rajka ; two comparable lesional area 20 50 cm2 distance least 5 cm , clinical condition atopic eczema mild moderate ( meet Hanifin Rajka´s criterion ; TEWL lesional area least 12 g/m²h , TEWL value difference ≤ 30 % allow lesional area ; physical examination must without disease finding unless investigator considers abnormality irrelevant outcome study ; sexually active female childbearing potential either surgically sterile hysterectomy tubal ligation ) , use medically accept contraceptive regimen : systemic contraceptive ( oral , implant , injection ) , diaphragm cervical cap intravaginal spermicide , intrauterine device ( IUD ) , condom intravaginal spermicide . acne , eczema atopic eczema , hyper hypopigmentation tattoo treatment area ; suntan opinion investigator prevents correct assessment darkskinned person whose skin color prevents ready assessment skin reaction ; evidence drug alcohol abuse ; pregnancy nursing ; UVtherapy within 6 week first treatment ; participation another clinical study involve pharmaceutical product 28 day precede study ; symptom clinically significant illness may influence outcome study four week study ; know allergic reaction component study preparation comparator ; treatment systemic locally act medication might counter influence study aim ( e.g . antihistamine glucocorticosteroids ) within two week begin study ( exception : asthma may find patient atopic eczema , therefore inhalation corticosteroid patient asthma accompany atopic eczema allow dose exceed 1 mg/day . The dosage remain constant throughout study period ) ; opinion investigator physician perform initial examination patient participate study , e.g . due probable noncompliance inability understand study give adequately informed consent ; patient institutionalized legal regulatory order .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>